z-logo
open-access-imgOpen Access
Role of self-expanding metal stents in the management of variceal haemorrhage: Hype or hope?
Author(s) -
Brian Hogan,
James O’Beirne
Publication year - 2016
Publication title -
world journal of gastrointestinal endoscopy
Language(s) - English
Resource type - Journals
ISSN - 1948-5190
DOI - 10.4253/wjge.v8.i1.23
Subject(s) - medicine , balloon tamponade , transjugular intrahepatic portosystemic shunt , portal hypertension , surgery , tamponade , bare metal , refractory (planetary science) , randomized controlled trial , portal vein thrombosis , stent , thrombosis , cirrhosis , restenosis , physics , astrobiology
Despite the advances of medical, endoscopic and radiological therapy over recent years the mortality rates of acute variceal haemorrhage are still 16%-20% and the medium term outcome has not improved in the last 25 years. Early transjugular intrahepatic portosystemic shunt has proved to be an effective therapy for selected groups of patients with a high risk of re-bleeding and moderate liver disease. However, there is an unmet need for a therapy that can be applied in patients with a high risk of re-bleeding and advanced liver disease either as definitive therapy or as a bridge to permanent therapy. Self-expanding metal stents can be placed without the need for endoscopic or fluoroscopic control and, once in place, will provide effective haemostasis and allow a route for oral fluids and nutrition. They can remain in place whilst liver function recovers and secondary prophylaxis is initiated. We review the results of 6 case series including a total of 83 patients and the first randomised controlled trial of self-expanding metal stents vs balloon tamponade (BT) in the management of refractory variceal haemorrhage. We report that self-expanding metal stents provide effective haemostasis and perform better than BT in refractory bleeding, where they are associated with fewer complications. Whilst the most effective place for self-expanding metal stents in the management algorithm needs to be determined by further randomised controlled trials, currently they provide an effective alternative to BT in selected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here